MX2020008181A - Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. - Google Patents
Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.Info
- Publication number
- MX2020008181A MX2020008181A MX2020008181A MX2020008181A MX2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A MX 2020008181 A MX2020008181 A MX 2020008181A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antigen
- binding fragment
- same
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810142118 | 2018-02-11 | ||
| PCT/CN2019/074397 WO2019154315A1 (zh) | 2018-02-11 | 2019-02-01 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008181A true MX2020008181A (es) | 2020-09-18 |
Family
ID=67548182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008181A MX2020008181A (es) | 2018-02-11 | 2019-02-01 | Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11472882B2 (https=) |
| EP (1) | EP3753951A4 (https=) |
| JP (2) | JP7393337B2 (https=) |
| CN (2) | CN116693686A (https=) |
| AU (1) | AU2019218319B2 (https=) |
| BR (1) | BR112020015736A2 (https=) |
| CA (1) | CA3089246A1 (https=) |
| MX (1) | MX2020008181A (https=) |
| TW (1) | TWI823895B (https=) |
| WO (1) | WO2019154315A1 (https=) |
| ZA (1) | ZA202004701B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| US20230072897A1 (en) * | 2019-06-06 | 2023-03-09 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
| CN115298220B (zh) * | 2020-03-24 | 2024-12-20 | 上海翰森生物医药科技有限公司 | 抗体-药物偶联物及其医药用途 |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| BR112022026508A2 (pt) | 2020-06-24 | 2023-03-07 | Prothena Biosciences Ltd | Anticorpos que reconhecem sortilina |
| CN117980332A (zh) * | 2020-08-18 | 2024-05-03 | Abl生物公司 | 抗b7-h4/抗4-1bb双特异性抗体及其应用 |
| MX2023008000A (es) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics Inc | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2023283345A1 (en) * | 2021-07-07 | 2023-01-12 | Incyte Corporation | Anti-b7-h4 antibodies and uses thereof |
| CA3238965A1 (en) * | 2021-12-01 | 2023-06-08 | Kadmon Corporation, Llc | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
| TW202342516A (zh) * | 2021-12-23 | 2023-11-01 | 愛爾蘭商普羅希那生物科學有限公司 | 識別分選蛋白的抗體 |
| KR20240163098A (ko) * | 2022-03-30 | 2024-11-18 | 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 | B7h4 항체-약물 접합체 및 이의 용도 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| TW202444431A (zh) * | 2023-04-12 | 2024-11-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗體藥物偶聯物在製備預防和／或治療癌症的藥物中的用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858710B2 (en) * | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US20030091580A1 (en) * | 2001-06-18 | 2003-05-15 | Mitcham Jennifer L. | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US8759490B2 (en) * | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| US8323645B2 (en) * | 2005-03-24 | 2012-12-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| US9676854B2 (en) * | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US9562099B2 (en) * | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP6436965B2 (ja) * | 2013-03-14 | 2018-12-12 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及びイムノコンジュゲート |
| CN103981150B (zh) * | 2014-03-28 | 2016-06-01 | 苏州大学 | 抗人b7-h4单克隆抗体及其制备和应用 |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| AU2016243126A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cells for the treatment of B7-H4 expressing solid tumors |
| CN109563503B (zh) * | 2016-07-26 | 2023-09-29 | 静冈县 | 抗b7-h4抗体 |
| CN107299085B (zh) * | 2017-05-26 | 2020-09-29 | 广东医科大学 | 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用 |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| KR20200144094A (ko) * | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| KR102227515B1 (ko) | 2018-12-18 | 2021-03-12 | 주식회사 포스코 | 제올라이트 및 그 제조방법 |
-
2019
- 2019-02-01 CN CN202310820681.5A patent/CN116693686A/zh active Pending
- 2019-02-01 WO PCT/CN2019/074397 patent/WO2019154315A1/zh not_active Ceased
- 2019-02-01 BR BR112020015736-8A patent/BR112020015736A2/pt unknown
- 2019-02-01 EP EP19750949.0A patent/EP3753951A4/en active Pending
- 2019-02-01 MX MX2020008181A patent/MX2020008181A/es unknown
- 2019-02-01 CN CN201980001361.9A patent/CN110366560B/zh active Active
- 2019-02-01 JP JP2020542138A patent/JP7393337B2/ja active Active
- 2019-02-01 CA CA3089246A patent/CA3089246A1/en active Pending
- 2019-02-01 US US16/967,016 patent/US11472882B2/en active Active
- 2019-02-01 AU AU2019218319A patent/AU2019218319B2/en active Active
- 2019-02-11 TW TW108104453A patent/TWI823895B/zh active
-
2020
- 2020-07-29 ZA ZA2020/04701A patent/ZA202004701B/en unknown
-
2023
- 2023-11-21 JP JP2023197481A patent/JP2024026132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089246A1 (en) | 2019-08-15 |
| US20210032347A1 (en) | 2021-02-04 |
| AU2019218319A1 (en) | 2020-08-13 |
| JP7393337B2 (ja) | 2023-12-06 |
| TW201934581A (zh) | 2019-09-01 |
| ZA202004701B (en) | 2023-12-20 |
| CN110366560B (zh) | 2023-07-28 |
| WO2019154315A1 (zh) | 2019-08-15 |
| CN110366560A (zh) | 2019-10-22 |
| JP2024026132A (ja) | 2024-02-28 |
| BR112020015736A2 (pt) | 2020-12-08 |
| CN116693686A (zh) | 2023-09-05 |
| TWI823895B (zh) | 2023-12-01 |
| EP3753951A4 (en) | 2022-03-16 |
| JP2021513331A (ja) | 2021-05-27 |
| RU2020124155A (ru) | 2022-03-11 |
| US11472882B2 (en) | 2022-10-18 |
| EP3753951A1 (en) | 2020-12-23 |
| AU2019218319B2 (en) | 2025-11-13 |
| KR20200119846A (ko) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008181A (es) | Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. | |
| MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| EP4406610A3 (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| EP4327866A3 (en) | Mirikizumab in the treatment of ulcerative colitis | |
| MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
| BR112016027881A2 (pt) | antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| MY209791A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| MX2020003034A (es) | Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. | |
| MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
| MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
| MX2019003779A (es) | Uso médico de un conjugado anticuerpo anti-c-met-fármaco citotóxico. |